FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback